Stemline Therapeutics, Inc.

( )
STML After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 1.08%63.831.0%$516.00m
AMGNAmgen, Inc. -1.17%222.951.3%$446.23m
BIIBBiogen, Inc. 1.08%281.141.4%$379.19m
ILMNIllumina, Inc. -1.77%313.923.5%$317.02m
VRTXVertex Pharmaceuticals, Inc. -0.74%227.371.9%$271.00m
REGNRegeneron Pharmaceuticals, Inc. -1.70%339.422.6%$234.71m
EXASEXACT Sciences Corp. -1.83%87.9324.0%$219.28m
ALXNAlexion Pharmaceuticals, Inc. 0.03%105.302.0%$170.88m
AAgilent Technologies, Inc. -1.92%86.571.6%$128.30m
INCYIncyte Corp. -0.87%76.072.5%$126.05m
SRPTSarepta Therapeutics, Inc. -0.69%111.6214.6%$107.26m
BMRNBioMarin Pharmaceutical, Inc. -1.78%84.624.3%$106.34m
SGENSeattle Genetics, Inc. -2.77%110.436.1%$101.02m
DERMDermira, Inc. 0.00%18.713.8%$83.32m
BLUEbluebird bio, Inc. -4.74%83.1214.2%$82.31m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.